HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT07587034
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • HTAC — PROCEDURE
    Patients will first undergo hepatic arterial infusion chemotherapy (HAIC) treatment. Subsequently, transarterial chemoembolization (TACE) will be administered sequentially following the completion of HAIC. This regimen will be combined with apatinib (a vascular endothelial growth factor receptor 2 \[VEGFR-2\] inhibitor) and camrelizumab (a programmed cell death protein 1 \[PD-1\] inhibitor) therapy.
  • HAC — PROCEDURE
    Patients will receive a combination therapy consisting of HAIC, apatinib, and camrelizumab.
  • TAC — PROCEDURE
    Patients will be treated with a regimen combining TACE, apatinib, and camrelizumab.

Study Details

To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.

Key Dates

First listed
May 14, 2026
Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
315 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HTAC Group
    Patients will first undergo hepatic arterial infusion chemotherapy (HAIC) treatment. Subsequently, transarterial chemoembolization (TACE) will be administered sequentially following the completion of HAIC. This regimen will be combined with apatinib (a vascular endothelial growth factor receptor 2 \[VEGFR-2\] inhibitor) and camrelizumab (a programmed cell death protein 1 \[PD-1\] inhibitor) therapy.
  • Experimental: HAC Group
    Patients will receive a combination therapy consisting of HAIC, apatinib, and camrelizumab.
  • Experimental: TAC Group
    Patients will be treated with a regimen combining TACE, apatinib, and camrelizumab.

Primary Outcome Measure

Progression-Free Survival (PFS) [Assessed by mRECIST Criteria] [ Time Frame: Up to 27 months. ]

Find similar trials

Nationwide
Liver cancer trialsOncology trialsGI oncology trialsHepatology trials

Related Studies